Experimental drugs for brain cancer show promise

05/23/2008 | NYTimes.com

Cancer experts hope several promising drugs will follow the success of Genentech's Avastin and Schering-Plough Corp.'s Temodar and reduce brain cancer deaths. An experimental vaccine bought by Pfizer from Avant Immunotherapeutics allowed early clinical trial patients to live twice longer than expected. A vaccine candidate in Northwest Biotherapeutics' pipeline also extended survival to at least three years among some of the patients in an early trial.

View Full Article in:

NYTimes.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Abbott
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA